Human Vaccines & Immunotherapeutics

OCT 19, 2026 · JOURNAL ARTICLE

GMMA as adjuvant and carrier for mucosal delivery of group A streptococcus glycoconjugate vaccine.

Human Vaccines & Immunotherapeutics

Group A streptococcus (GAS) infection is usually initiated by colonization of mucosal sites such as the pharynx, followed by invasion and systemic dissemination. Development of a v

OCT 15, 2026 · JOURNAL ARTICLE

Safety and immunogenicity of a first-generation modified vaccinia virus Ankara-vectored SARS-CoV-2 vaccine candidate with mRNA-based booster vaccination: A phase 1 trial.

Human Vaccines & Immunotherapeutics

The rapid development of effective COVID-19 vaccines was enabled by the parallel assessment of multiple candidates early in the pandemic, including candidates based on the Modified

OCT 8, 2026 · JOURNAL ARTICLE

Optimizing pneumococcal prevention in South African older adults: Cost-effectiveness of PCV20 versus PPSV23 in the context of HIV-associated risk.

Human Vaccines & Immunotherapeutics

Pneumococcal disease remains a major cause of morbidity and mortality among older adults in South Africa, particularly among people living with HIV. Evidence on the cost-effectiven

OCT 2, 2026 · JOURNAL ARTICLE

Engineered nanovaccines for prophylactic and therapeutic immunotherapy against cancer and infectious disease.

Human Vaccines & Immunotherapeutics

Nanotechnology has transformed vaccine development by engineering nanovaccines that offer precise control over antigen performance, immune modulation and targeted delivery. These p

OCT 1, 2026 · JOURNAL ARTICLE

12th Immunotherapy of Cancer Conference (ITOC12): A meeting report.

Human Vaccines & Immunotherapeutics

The Immunotherapy of Cancer (ITOC) meeting is a leading international conference that unites immuno-oncology researchers and clinicians from around the world to present and discuss

SEP 30, 2026 · JOURNAL ARTICLE

The intrinsic, instrumental, and symbolic values of sustaining childhood vaccination in conflict settings.

Human Vaccines & Immunotherapeutics

The World Health Organization's Decision Framework for Vaccination in Acute Humanitarian Emergencies remains the principal global guide for vaccination prioritization and decision-

SEP 25, 2026 · JOURNAL ARTICLE

Coverage and appropriateness of influenza vaccination in adults ≥ 60 y: Provider contribution and adherence to Italian national recommendations.

Human Vaccines & Immunotherapeutics

The aim of the present study is to evaluate the 2023/24 and 2024/25 influenza vaccination campaigns in Liguria (Italy), specifically analyzing how the transition toward a proximity

SEP 14, 2026 · JOURNAL ARTICLE

Healthcare resource use and costs following RSV-related hospitalizations among US adults aged 50 years and older.

Human Vaccines & Immunotherapeutics

Respiratory syncytial virus (RSV), a common virus causing acute respiratory illness (ARI), can lead to severe disease among adults aged ≥50 y. We assessed healthcare resource utili